Medicare Part D Rebate Reporting: When a Rebate Becomes a Service Fee

Medicare Part D rebate reporting fraud can inflate federal payments when a sponsor disguises manufacturer rebates as service fees in its DIR reports. The money lowers drug costs inside the business, but the report keeps that saving out of Medicare’s calculation. If you work in rebate contracting, finance or sponsor reporting, you may know who chose the category and what the manufacturer actually paid for.

Direct and indirect remuneration, usually called DIR, includes rebates and other concessions that reduce a sponsor’s drug costs. A pharmacy benefit manager may negotiate and keep the money. The sponsor still has to account for the concession in its reporting to Medicare. The pharmacy transaction, the rebate payment and the government’s final payment belong to the same financial story, but they appear in different records.

How Part D DIR Reaches Medicare’s Payment

Medicare pays Part D sponsors during the coverage year, then reconciles payments against actual costs and other payment information.

The sponsor’s bid estimates the cost of providing drug coverage, including anticipated price concessions. The Centers for Medicare & Medicaid Services makes subsidy payments during the year based in part on that bid. When a beneficiary fills a covered prescription, the sponsor sends the agency a prescription drug event record, or PDE, containing information about the drug, pharmacy, costs and payments. Annual DIR reporting adds the later concessions to that cost picture.

An omitted rebate can leave the government paying against costs that the business has already reduced.

Summary DIR and Detailed DIR Serve Different Purposes

Summary DIR supplies plan-level information for Part D payment reconciliation. Detailed DIR breaks information down by drug for the federal branded-drug manufacturer fee process. That manufacturer fee is a separate federal assessment, distinct from the service fees a manufacturer might pay a PBM.

The Centers for Medicare & Medicaid Services’ reporting guidance for contract year 2022 separates the Summary report at the plan-benefit-package level from the Detailed report at the 11-digit National Drug Code level. Its attestation memorandum for the 2025 reconciliation retains the distinction between payment data and manufacturer-fee data.

The 2022 guidance included good-faith estimates of remuneration expected for the contract year but not yet received. For rebates tied to a particular drug, CMS preferred allocation based on actual use of that drug when possible. The allocation connects a manufacturer payment to the plans and prescriptions that earned it.

Part D Service Fees and Rebate Reporting

Part D service fees and rebate reporting turn on what the manufacturer paid for. A qualifying bona fide service fee is excluded from DIR. A manufacturer rebate reduces drug costs and belongs in DIR even when a PBM keeps it.

The commercial bargain starts before anyone prepares the report. The Medicare Payment Advisory Commission’s June 2023 report, Assessing Postsale Rebates for Prescription Drugs in Medicare Part D, describes manufacturers negotiating rebates for favorable placement on a plan’s formulary, the list of drugs it covers. Competing brands give a PBM bargaining power. The report also found that larger insurers with their own PBMs and pharmacies had greater leverage to negotiate concessions from manufacturers and pharmacies.

That makes the fee description consequential. Is the manufacturer paying for work performed on its behalf, or giving a discount to secure drug sales? CMS’s 2022 reporting guidance sets out the conditions for a bona fide service fee:

• The fee pays for an itemized service actually performed for the manufacturer.
• The manufacturer would otherwise perform the service or hire someone to do it.
• The fee reflects fair market value.
• The recipient does not pass the fee through to a client or customer.

The Centers for Medicare & Medicaid Services also calls for the sponsor to retain the manufacturer’s fair-market-value analysis, including its assumptions, method and rationale. Where a fee otherwise qualifies but exceeds fair market value, the excess belongs in DIR.

The 2022 Summary DIR report puts PBM Retained Rebates in DIR #1 and All Other Rebates in DIR #3, including rebates passed through to the sponsor. DIR #4, Administrative Service Fees Reported as DIR, carries the portion above fair market value when a fee otherwise qualifies.

The separate Bona Fide Service Fees field is excluded from total DIR. Those fees therefore do not reduce the allowable costs used in the reinsurance and risk-corridor calculations. A number can be disclosed to CMS and still be put in the category that keeps it out of the cost reduction.

The same guidance separately collects PBM spread, the difference between what a sponsor pays the PBM and what the PBM pays a pharmacy, without treating that spread as DIR. It also separates administrative incentive payments to PBMs. For an insider, the payer, recipient, contract and work performed explain more than the word fee on a spreadsheet.

The Elixir Rebate-Reporting Settlement

Elixir Insurance Company and Rite Aid agreed to pay $101 million in a civil settlement announced in July 2024 over allegedly false rebate reporting. The government alleged that manufacturer rebates were reported as bona fide service fees even though the manufacturers had not negotiated to pay those fees.

Elixir Insurance offered Part D plans. Elixir Rx Options and Elixir Rx Solutions provided PBM services, including negotiating rebates. The government’s allegations covered the sponsor’s DIR reports from 2014 through 2020 and asserted that the retained rebates failed the service-fee definition. The alleged benefit was keeping rebates inside the business while denying Medicare the corresponding reduction in reported drug costs.

The case began with a former employee who had worked in finance and underwriting. The government joined the whistleblower’s case. The Justice Department’s Civil Division and the U.S. Attorney’s Office for the Northern District of Ohio handled the case, with investigative assistance from the Department of Health and Human Services’ Office of Inspector General and the FBI’s Cleveland office.

The Valuation Documents Behind the Fee

The whistleblower’s complaint alleged that the retained amounts were tied to rebates rather than the quantity and value of services performed. It also alleged that the arrangement was used for the affiliated Part D plan, despite the PBM serving other plans. The supporting paperwork was part of the allegation:

The complaint also alleged that Rite Aid’s chief executive and chief financial officer learned of the arrangement, expressed concern and allowed it to continue. Those allegations put the valuation work, the internal warnings and the decision to keep reporting the fees in the same story.

We see the absurdity in the alleged arrangement: a service fee for work the manufacturer had not agreed to buy.

The Percentage Changed Its Base

The government’s allegations in the signed settlement agreement describe different calculations for the retained amounts: 20% of estimated manufacturer rebates from 2014 through 2019, then 5.5% of the wholesale acquisition cost of rebateable drugs in 2020.

The alleged calculation moved from a share of the rebate pool to a share of the drug-price base.

Sponsor Certification of Part D Remuneration

Sponsor certification of Part D remuneration connects the reported numbers to the people responsible for their accuracy. The sponsor retains ultimate responsibility under its CMS contract even when a PBM or another contractor performs the work.

The Centers for Medicare & Medicaid Services’ guidance for 2022 required sponsors to certify each DIR report as accurate, complete and truthful to the best of their knowledge. Sponsors also had to retain documentation verifying certifications from the contractors that generated or submitted the information.

The officer’s signature belongs beside the version of the report that went to CMS. The underlying contracts, valuation analyses and communications explain what that officer and the reporting team knew. In the Elixir complaint, the whistleblower alleged that the sponsor’s president signed and certified reports containing the misclassified amounts. The alleged internal concerns make the approval trail especially relevant.

This is where a finance or compliance employee’s knowledge can make the difference. You may know why an amount moved between categories, who approved the treatment and whether a concern reached the person signing. We connect that account to the report and the payment it affected.

Pharmacy Concessions After the 2024 Change

Pharmacy price concessions moved into the point-of-sale negotiated price beginning in 2024, including performance-based concessions assessed later. That change did not apply to manufacturer rebates.

MedPAC’s July 2026 Data Book reports about $92 billion in DIR for 2023 and $79 billion for 2024, attributing the decline to pharmacy concessions moving to the point of sale. The reporting location changed.

For pharmacy and sponsor employees, the remittance, contract and drug-cost report connect the adjustment to Medicare’s payment. Manufacturer rebates still need to be traced to the service-fee amounts reported separately.

A False DIR Report and Reconciliation Payment

A false DIR report and reconciliation payment connect through the drug costs CMS uses to settle with the sponsor. The accepted report, subsequent corrections and reconciliation result show where a misclassified concession affected the federal calculation.

In a 2020 audit of Horizon Blue Cross Blue Shield’s pharmacy-fee reporting, the Department of Health and Human Services’ Office of Inspector General compared the sponsor’s reports with submissions to CMS, pharmacy and PBM contracts, PDE data, pharmacy remittance advices and supporting fee documents. That method connects the records on both sides of the pharmacy payment to the sponsor’s report.

The 2022 guidance places claim-level drug-cost corrections in adjusted PDE records, rather than the All Other DIR field. Later rebates, settlements or audit findings can instead change the Summary DIR total.

A corrected pharmacy transaction, a changed DIR total and a revised federal payment leave different records. We follow the change through to Medicare’s final payment calculation.

The broader work of connecting Medicare fraud evidence brings the business records and the decisions together. In rebate reporting, that means the manufacturer agreement and payment, the service description and valuation, the sponsor’s submission, the approval communications and the resulting payment calculation. Someone in rebate operations may understand the contract while someone in finance sees the category used for CMS. Their accounts can explain the same missing discount from different sides.

Does the False Claims Act Apply to Medicare?

Yes. The False Claims Act reaches knowingly false payment claims involving Medicare, including the rebate-reporting allegations resolved in the Elixir civil settlement. The payment issue here is what the sponsor told CMS about drug costs and what that representation did to the federal payment.

For a health care insider, the business decision can be as revealing as the number. A valuation created to justify a predetermined amount, a warning passed to an executive or a reporting category kept after a concern was raised can explain why the same treatment continued. We examine those connections with you and bring in Medicare Part D fraud whistleblower lawyers who understand sponsor reporting and PBM arrangements.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Why the Category Changed

If your healthcare work gives you the contracts, rebate reports or valuation papers behind a rebate turned into a service fee, speak with our whistleblower experts about the reporting decision. We work beside you to build a case that connects the money, the manufacturer agreement and the sponsor’s certification, with Medicare Part D fraud whistleblower lawyers who know where those records meet. We stay with you through the case.